Cargando…

Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma: A case report

RATIONAL: Epidermal growth factor receptor (EGFR) 20 exon insertion is the second most common EGFR aberrations in non-small cell lung cancer (NSCLC). Despite some novel EGFR inhibitors, clinically obtainable management for this subset of patients remains an unmet need. there are no previous reports...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nong, Jingying, Gu, Yanfei, Yao, Shuyang, Zhang, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294870/ https://www.ncbi.nlm.nih.gov/pubmed/34398022 http://dx.doi.org/10.1097/MD.0000000000026650

Ejemplares similares

Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report
por: Zhao, Nan, et al.
Publicado: (2022)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Lung adenocarcinoma with EGFR gene mutation metastatic to the uterine cervix: A case report
por: Wang, Yong, et al.
Publicado: (2020)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
por: Zhang, Xinyong, et al.
Publicado: (2020)

Not All EGFR Exon 20 Insertions Are Created Equal
por: Lin, Yen-Ting, et al.
Publicado: (2020)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
por: Chen, Xuesong, et al.
Publicado: (2023)

Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations
por: Wang, Lifeng, et al.
Publicado: (2022)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
por: Lin, Huamao M., et al.
Publicado: (2022)

Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report
por: Jiang, Yiqian, et al.
Publicado: (2021)

Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2018)

Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report
por: Tang, Haifeng, et al.
Publicado: (2023)

S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial
por: Du, Feng, et al.
Publicado: (2015)

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
por: Chen, Yan, et al.
Publicado: (2022)

Breast metastasis from EGFR/ALK negative lung adenocarcinoma: A case report
por: Cao, Liyu, et al.
Publicado: (2020)

Nivolumab plus regorafenib in patients with small bowel adenocarcinoma: A case report
por: Zhang, Gairong, et al.
Publicado: (2021)

Bone metastatic carcinoma with EGFR amplification and mutation: A case report and literature review
por: Du, Hong-Juan, et al.
Publicado: (2023)

Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma
por: Isaka, Tetsuya, et al.
Publicado: (2015)

Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma
por: Ju, Qing, et al.
Publicado: (2021)

Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
por: Tamirat, Mahlet Z., et al.
Publicado: (2021)

EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma
por: Pacini, Laura, et al.
Publicado: (2022)

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis
por: Chen, Datian, et al.
Publicado: (2018)

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
por: Chen, Yu, et al.
Publicado: (2015)

Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report
por: Tan, Xiang, et al.
Publicado: (2017)

Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report
por: Qin, Ruo-Yan, et al.
Publicado: (2021)

Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series
por: Li, Shih-Hong, et al.
Publicado: (2015)

Long-term survival in a patient with advanced non-smoking lung adenocarcinoma and no EGFR mutation after comprehensive therapy with EGFR-TKI-based therapy: A case report
por: Zhang, Qianyu, et al.
Publicado: (2022)

A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial
por: Chen, Ming-Huang, et al.
Publicado: (2016)

Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study
por: Liu, Tingjun, et al.
Publicado: (2023)

Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis
por: Bai, Long, et al.
Publicado: (2016)

Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
por: Zhang, Ping, et al.
Publicado: (2018)

Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI: A case report
por: Chen, Hui Jun, et al.
Publicado: (2021)

Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma
por: Tie, Xiaowei, et al.
Publicado: (2022)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report
por: Xu, Tongpeng, et al.
Publicado: (2017)

High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs
por: Deng, Chao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fo8q6orl20978c249u6gsc4j1s